Detalhe da pesquisa
1.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239405
2.
Association between overweight, obesity, and quality of life of patients receiving an anticancer treatment for prostate cancer: a systematic literature review.
Health Qual Life Outcomes
; 21(1): 11, 2023 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36721272
3.
Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associé à La Grossesse) network.
Acta Oncol
; 61(3): 302-308, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779355
4.
The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey.
Future Oncol
; 17(2): 151-157, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33305604
5.
Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update.
Int J Mol Sci
; 22(12)2021 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34205414
6.
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Breast Cancer Res Treat
; 177(2): 383-393, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31172407
7.
The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Lab Invest
; 98(6): 696-707, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29491426
8.
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Oncologist
; 23(10): 1137-1143, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30018134
9.
Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy.
Cancer Cell Int
; 18: 175, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455595
10.
New anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodies.
Curr Opin Oncol
; 29(6): 405-410, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28984651
11.
Neglected giant benign phyllode tumor of the breast.
Eur J Nucl Med Mol Imaging
; 49(11): 3954-3955, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583825
12.
A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.
Chemotherapy
; 61(1): 15-22, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26528705
13.
Pertuzumab and trastuzumab: the rationale way to synergy.
An Acad Bras Cienc
; 88 Suppl 1: 565-77, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27275646
14.
Severe acute respiratory syndrome Coronavirus 2 infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible?
Int J Cancer
; 147(12): 3576-3578, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32574373
15.
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Oncologist
; 20(8): 873-9, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26112003
16.
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(12): 1351-60, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273343
17.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(11): 1269-78, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273342
18.
Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.
BMC Cancer
; 14: 991, 2014 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25535397
19.
Early HER2-positive breast cancers: time for a new revolution?
Lancet Oncol
; 19(1): 12-13, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29175146
20.
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Lancet Oncol
; 14(10): 962-70, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23965225